News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

rEVO Biologics Initiates PRESERVE-1 Phase 3 Clinical Trial For ATryn® In Early-Onset Preeclampsia



3/31/2014 8:06:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn® [antithrombin (Recombinant)] for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy. Preeclampsia at this stage of pregnancy is rare and extremely serious, occurring in a subset of all preeclampsia patients. The objective of the PRESERVE-1 trial is to assess whether ATryn prolongs pregnancy in mothers with early-onset preeclampsia and consequently improves the health of their babies.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES